$TWST

Finn Patrick John sold $246K of TWST

Finn Patrick John (President and COO) sold 2,888 shares of Twist Bioscience Corp (TWST) at $85.32 ($0.25M total) on 2026-08-03.

Original reporting
SEC EDGAR · Finn Patrick John
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around TWST due to insider selling, but there is no new operational, financial, or regulatory information in the text.

02

Market read

A single insider open-market sale is disclosed, which can slightly affect sentiment but is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

No 10b5-1 plan is stated, but the filing does not explain motive; also, insider sales can be frequent and not correlated with near-term fundamentals without accompanying buys, guidance changes, or operational events.

Relevance 4/10Novelty 3/10Timing: filed Aug 5, transaction dated Aug 3 (after-hours/next session context)

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience, reported via SEC EDGAR.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience Form 4 shows COO Finn Patrick John sold 2,888 shares for about $246.4K at $85.3212 on Aug 3.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other news.

Evidence & confidence

The filing is primary-source and company-specific, but insider sales alone usually do not change earnings power or guidance. The absence of a disclosed 10b5-1 plan can add minor interpretive noise, yet the transaction size is modest relative to a large-cap context and no other operational catalyst is provided.

Market effects

Minimal. Insider sale does not provide new biotech/biomanufacturing sector information.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned personal liquidity needs, so it may not reflect negative company expectations.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Finn Patrick John

    President and COO who sold 2,888 shares of TWST.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.